Stereospecific lasofoxifene derivatives reveal the interplay between estrogen receptor alpha stability and antagonistic activity in ESR1 mutant breast cancer cells

被引:27
作者
Hosfield, David J. [1 ]
Weber, Sandra [2 ]
Li, Nan-Sheng [1 ]
Suavage, Madline [2 ]
Joiner, Carstyn F. [3 ]
Hancock, Govinda R. [3 ]
Sullivan, Emily A. [3 ]
Ndukwe, Estelle [1 ]
Han, Ross [1 ]
Cush, Sydney [1 ]
Laine, Muriel [1 ,2 ]
Mader, Sylvie C.
Greene, Geoffrey L. [1 ]
Fanning, Sean W. [3 ]
机构
[1] Univ Chicago, Ben May Dept Canc Res, Chicago, IL 60637 USA
[2] Univ Montreal, Inst Res Immunol & Canc, Montreal, PQ, Canada
[3] Loyola Univ Chicago, Dept Canc Biol, Maywood, IL 60637 USA
关键词
breast cancer; Y537S ESR1 Mutation; antiestrogen; hormone resistance; drug resistance; estrogen receptor degradation; D538G ESR1 Mutation; E; coli; Human; ESR1; MUTATIONS; BINDING; TAMOXIFEN; EFFICACY; THERAPY; POTENT;
D O I
10.7554/eLife.72512
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Chemical manipulation of estrogen receptor alpha ligand binding domain structural mobility tunes receptor lifetime and influences breast cancer therapeutic activities. Selective estrogen receptor modulators (SERMs) extend estrogen receptor alpha (ER alpha) cellular lifetime/accumulation. They are antagonists in the breast but agonists in the uterine epithelium and/or in bone. Selective estrogen receptor degraders/downregulators (SERDs) reduce ER alpha cellular lifetime/accumulation and are pure antagonists. Activating somatic ESR1 mutations Y537S and D538G enable resistance to first-line endocrine therapies. SERDs have shown significant activities in ESR1 mutant setting while few SERMs have been studied. To understand whether chemical manipulation of ER alpha cellular lifetime and accumulation influences antagonistic activity, we studied a series of methylpyrollidine lasofoxifene (Laso) derivatives that maintained the drug's antagonistic activities while uniquely tuning ER alpha cellular accumulation. These molecules were examined alongside a panel of antiestrogens in live cell assays of ER alpha cellular accumulation, lifetime, SUMOylation, and transcriptional antagonism. High-resolution x-ray crystal structures of WT and Y537S ER alpha ligand binding domain in complex with the methylated Laso derivatives or representative SERMs and SERDs show that molecules that favor a highly buried helix 12 antagonist conformation achieve the greatest transcriptional suppression activities in breast cancer cells harboring WT/Y537S ESR1. Together these results show that chemical reduction of ER alpha cellular lifetime is not necessarily the most crucial parameter for transcriptional antagonism in ESR1 mutated breast cancer cells. Importantly, our studies show how small chemical differences within a scaffold series can provide compounds with similar antagonistic activities, but with greatly different effects of the cellular lifetime of the ER alpha, which is crucial for achieving desired SERM or SERD profiles.
引用
收藏
页数:27
相关论文
共 45 条
[1]  
Abe O, 2005, LANCET, V366, P2087, DOI 10.1016/s0140-6736(05)66544-0
[2]   The Dysregulated Pharmacology of Clinically Relevant ESR1 Mutants is Normalized by Ligand-activated WT Receptor [J].
Andreano, Kaitlyn J. ;
Baker, Jennifer G. ;
Park, Sunghee ;
Safi, Rachid ;
Artham, Sandeep ;
Oesterreich, Steffi ;
Jeselsohn, Rinath ;
Brown, Myles ;
Sammons, Sarah ;
Wardell, Suzanne E. ;
Chang, Ching-yi ;
Norris, John D. ;
McDonnell, Donald P. .
MOLECULAR CANCER THERAPEUTICS, 2020, 19 (07) :1395-1405
[3]  
Anurag Meenakshi, 2018, Oncotarget, V9, P36252, DOI 10.18632/oncotarget.26363
[4]   Dose-escalation study of SAR439859, an oral selective estrogen receptor (ER) degrader (SERD), in postmenopausal women with ER+/HER2-metastatic breast cancer (mBC). [J].
Bardia, Aditya ;
Linden, Hannah M. ;
Ulaner, Gary A. ;
Chandarlapaty, Sarat ;
Gosselin, Alice ;
Doroumian, Severine ;
Celanovic, Marina ;
Campone, Mario .
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[5]   Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update [J].
Burstein, Harold J. ;
Lacchetti, Christina ;
Anderson, Holly ;
Buchholz, Thomas A. ;
Davidson, Nancy E. ;
Gelmon, Karen A. ;
Giordano, Sharon H. ;
Hudis, Clifford A. ;
Solky, Alexander J. ;
Stearns, Vered ;
Winer, Eric P. ;
Griggs, Jennifer J. .
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (05) :423-+
[6]   Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer A Secondary Analysis of the BOLERO-2 Clinical Trial [J].
Chandarlapaty, Sarat ;
Chen, David ;
He, Wei ;
Sung, Patricia ;
Samoila, Aliaksandra ;
You, Daoqi ;
Bhatt, Trusha ;
Patel, Parul ;
Voi, Maurizio ;
Gnant, Michael ;
Hortobagyi, Gabriel ;
Baselga, Jose ;
Moynahan, Mary Ellen .
JAMA ONCOLOGY, 2016, 2 (10) :1310-1315
[7]   Monitoring ligand-dependent assembly of receptor ternary complexes in live cells by BRETFect [J].
Cotnoir-White, David ;
El Ezzy, Mohamed ;
Boulay, Pierre-Luc ;
Rozendaal, Marieke ;
Bouvier, Michel ;
Gagnon, Etienne ;
Mader, Sylvie .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2018, 115 (11) :E2653-E2662
[8]   Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist [J].
De Savi, Chris ;
Bradbury, Robert H. ;
Rabow, Alfred A. ;
Norman, Richard A. ;
de Almeida, Camila ;
Andrews, David M. ;
Ballard, Peter ;
Buttar, David ;
Callis, Rowena J. ;
Currie, Gordon S. ;
Curwen, Jon O. ;
Davies, Chris D. ;
Donald, Craig S. ;
Feron, Lyman J. L. ;
Gingell, Helen ;
Glossop, Steven C. ;
Hayter, Barry R. ;
Hussain, Syeed ;
Karoutchi, Galith ;
Lamont, Scott G. ;
MacFaul, Philip ;
Moss, Thomas A. ;
Pearson, Stuart E. ;
Tonge, Michael ;
Walker, Graeme E. ;
Weir, Hazel M. ;
Wilson, Zena .
JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (20) :8128-8140
[9]  
Dickler MN., 2018, CANCER RES, V78, pD5, DOI [10.1158/1538-7445.SABCS17-PD5-10, DOI 10.1158/1538-7445.SABCS17-PD5-10]
[10]   Specific stereochemistry of OP-1074 disrupts estrogen receptor alpha helix 12 and confers pure antiestrogenic activity [J].
Fanning, S. W. ;
Hodges-Gallagher, L. ;
Myles, D. C. ;
Sun, R. ;
Fowler, C. E. ;
Plant, I. N. ;
Green, B. D. ;
Harmon, C. L. ;
Greene, G. L. ;
Kushner, P. J. .
NATURE COMMUNICATIONS, 2018, 9